Similar A1C Reductions, Less Hypoglycemia with Xultophy Compared to Basal-Bolus Tx

Xultophy 100/3.6 proved non-inferior to insulin glargine U100 in combination with insulin aspart in lowering HbA1c
Xultophy 100/3.6 proved non-inferior to insulin glargine U100 in combination with insulin aspart in lowering HbA1c

This article is part of MPR's coverage of the American Diabetes Association's 77th Scientific Sessions (ADA 2017), taking place in San Diego, CA. Our staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back regularly for more news from ADA 2017.


At the American Diabetes Association 77th Scientific Sessions, study authors presented new data from the Phase 3b DUAL VII clinical study showing that Xultophy 100/3.6 (insulin degludec and liraglutide) achieved similar HbA1c reductions with weight loss and significantly less hypoglycemia vs. basal-bolus therapy (insulin glargine U100 and insulin aspart). 

In the 26-week, randomized, open-label, multicenter study, Xultophy 100/3.6 proved non-inferior to insulin glargine U100 in combination with insulin aspart in lowering HbA1c in patients with type 2 diabetes. Patients treated with Xultophy 100/3.6 compared to basal-bolus therapy reached similar glycemic targets: A1c <7% (66.0% vs. 67.0%) and A1c ≤6.5% (49.6% vs. 44.6%). 

Patients treated with Xultophy 100/3.6 also had an 89% reduction in severe or blood glucose confirmed symptomatic hypoglycemic events (P<0.0001) as well as a 92% reduction in nocturnal severe or blood glucose confirmed symptomatic hypoglycemic events (P<0.0001). Regarding body weight, patients in the Xultophy 100/3.6 group had a weight loss of 0.93kg vs. a weight gain of 2.64kg in the basal-bolus group (P<0.0001). 

Compared to basal-bolus therapy, Xultophy 100/3.6-treated patients achieved A1c <7% with no hypoglycemia and no weight gain in the last 12 weeks (38.2% vs. 6.4%, respectively; OR 10.39, 95% CI: 5.76, 18.75). Moreover, patients in the Xultophy 100/3.6 group used a lower daily insulin dose vs. the basal-bolus group (40 Units vs. 84 Units; P<0.0001). 

Xultophy 100/3.6 is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 50 Units daily) or liraglutide (less than or equal to 1.8mg daily). 

For more information call (800) 727-6500 or visit Xultophy10036.com.


Visit MPR's conference section for continuous coverage from ADA 2017


Related Articles